{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:54Z","timestamp":1793159154325,"version":"4.5.0"},"reference-count":288,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02641-4","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:37:32Z","timestamp":1742301452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9716-636X","authenticated-orcid":false,"given":"Disha D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-2900","authenticated-orcid":false,"given":"Neha R.","family":"Raghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4989-2913","authenticated-orcid":false,"given":"Rajanikant","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand A.","family":"Kashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":false,"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2641_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/inorganics12120331","author":"Q Dong","year":"2024","unstructured":"Dong Q, Jiang Z. Platinum-iron nanoparticles for oxygen-enhanced sonodynamic tumor cell suppression. Inorganics. 2024. https:\/\/doi.org\/10.3390\/inorganics12120331.","journal-title":"Inorganics"},{"issue":"10","key":"2641_CR2","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1039\/D4CC06510G","volume":"61","author":"C Zhao","year":"2025","unstructured":"Zhao C, Song W, Wang J, Tang X, Jiang Z. Immunoadjuvant-functionalized metal\u2013organic frameworks: synthesis and applications in tumor immune modulation. Chem Commun. 2025;61(10):1962\u201377. https:\/\/doi.org\/10.1039\/D4CC06510G.","journal-title":"Chem Commun"},{"issue":"1","key":"2641_CR3","doi-asserted-by":"publisher","first-page":"25331","DOI":"10.1038\/s41598-024-76798-9","volume":"14","author":"Z Cao","year":"2024","unstructured":"Cao Z, Zhu J, Wang Z, Peng Y, Zeng L. Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses. Sci Rep. 2024;14(1):25331. https:\/\/doi.org\/10.1038\/s41598-024-76798-9.","journal-title":"Sci Rep"},{"key":"2641_CR4","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/ijn.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, et al. Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomed. 2024;19:5837\u201358. https:\/\/doi.org\/10.2147\/ijn.S466042.","journal-title":"Int J Nanomed"},{"issue":"17","key":"2641_CR5","doi-asserted-by":"publisher","first-page":"21546","DOI":"10.1021\/acsami.4c00793","volume":"16","author":"Y Chen","year":"2024","unstructured":"Chen Y, Deng Y, Li Y, Qin Y, Zhou Z, Yang H, et al. Oxygen-independent radiodynamic therapy: radiation-boosted chemodynamics for reprogramming the tumor immune environment and enhancing antitumor immune response. ACS Appl Mater Interfaces. 2024;16(17):21546\u201356. https:\/\/doi.org\/10.1021\/acsami.4c00793.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2641_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56010015","author":"B Arneth","year":"2019","unstructured":"Arneth B. Tumor microenvironment. Medicina (Kaunas, Lithuania). 2019. https:\/\/doi.org\/10.3390\/medicina56010015.","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"2641_CR7","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8776","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Jiang T, Wang J. Role of LMO7 in cancer (Review). Oncology reports. 2024. https:\/\/doi.org\/10.3892\/or.2024.8776.","journal-title":"Oncology reports"},{"key":"2641_CR8","doi-asserted-by":"publisher","first-page":"113993","DOI":"10.1016\/j.biopha.2022.113993","volume":"157","author":"D Sun","year":"2023","unstructured":"Sun D, Li X, Nie S, Liu J, Wang S. Disorders of cancer metabolism: The therapeutic potential of cannabinoids. Biomed Pharmacother. 2023;157:113993. https:\/\/doi.org\/10.1016\/j.biopha.2022.113993.","journal-title":"Biomed Pharmacother"},{"key":"2641_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106674","volume":"138","author":"H Yin","year":"2023","unstructured":"Yin H, Fu XY, Gao HY, Ma YN, Yao JF, Du SS, et al. Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates. Bioorg Chem. 2023;138: 106674. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106674.","journal-title":"Bioorg Chem"},{"issue":"8","key":"2641_CR10","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.21037\/qims-23-1028","volume":"14","author":"X Yao","year":"2024","unstructured":"Yao X, Zhu Y, Huang Z, Wang Y, Cong S, Wan L, et al. Fusion of shallow and deep features from (18)F-FDG PET\/CT for predicting EGFR-sensitizing mutations in non-small cell lung cancer. Quant Imaging Med Surg. 2024;14(8):5460\u201372. https:\/\/doi.org\/10.21037\/qims-23-1028.","journal-title":"Quant Imaging Med Surg"},{"key":"2641_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.semcdb.2019.05.010","volume":"98","author":"I Kurelac","year":"2020","unstructured":"Kurelac I, Umesh Ganesh N, Iorio M, Porcelli AM, Gasparre G. The multifaceted effects of metformin on tumor microenvironment. Semin Cell Dev Biol. 2020;98:90\u20137. https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.010.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"2641_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-018-0006-7","volume":"18","author":"S Maman","year":"2018","unstructured":"Maman S, Witz IP. A history of exploring cancer in context. Nat Rev Cancer. 2018;18(6):359\u201376. https:\/\/doi.org\/10.1038\/s41568-018-0006-7.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2641_CR13","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1021\/acs.jmedchem.3c02232","volume":"67","author":"XY Fu","year":"2024","unstructured":"Fu XY, Yin H, Chen XT, Yao JF, Ma YN, Song M, et al. Three rounds of stability-guided optimization and systematical evaluation of oncolytic peptide LTX-315. J Med Chem. 2024;67(5):3885\u2013908. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02232.","journal-title":"J Med Chem"},{"issue":"3","key":"2641_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/ppo.0000000000000118","volume":"21","author":"VS LeBleu","year":"2015","unstructured":"LeBleu VS. Imaging the tumor microenvironment. Cancer J (Sudbury, Mass). 2015;21(3):174\u20138. https:\/\/doi.org\/10.1097\/ppo.0000000000000118.","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"2641_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cyto.2016.01.021","volume":"89","author":"KV Korneev","year":"2017","unstructured":"Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine. 2017;89:127\u201335. https:\/\/doi.org\/10.1016\/j.cyto.2016.01.021.","journal-title":"Cytokine"},{"issue":"7","key":"2641_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrd4253","volume":"13","author":"DR Pattabiraman","year":"2014","unstructured":"Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discovery. 2014;13(7):497\u2013512. https:\/\/doi.org\/10.1038\/nrd4253.","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"2641_CR17","doi-asserted-by":"publisher","DOI":"10.3788\/COL202018.051701","volume":"18","author":"X Ma","year":"2020","unstructured":"Ma X, Cheng H, Hou J, Jia Z, Wu G, L\u00fc X, et al. Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure. Chin Opt Lett. 2020;18(5): 051701.","journal-title":"Chin Opt Lett"},{"issue":"1","key":"2641_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina56010015","volume":"56","author":"B Arneth","year":"2019","unstructured":"Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56(1):15. https:\/\/doi.org\/10.3390\/medicina56010015.","journal-title":"Medicina (Kaunas)"},{"issue":"13","key":"2641_CR19","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1182\/blood-2011-07-369736","volume":"119","author":"JK Tietze","year":"2012","unstructured":"Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood. 2012;119(13):3073\u201383. https:\/\/doi.org\/10.1182\/blood-2011-07-369736.","journal-title":"Blood"},{"key":"2641_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.25259\/Cytojournal_27_2023","volume":"20","author":"LJ Layfield","year":"2023","unstructured":"Layfield LJ. Grey zones in respiratory cytology: atypical or suspicious for malignancy and neoplasms of unknown malignant potential. CytoJournal. 2023;20:42. https:\/\/doi.org\/10.25259\/Cytojournal_27_2023.","journal-title":"CytoJournal"},{"key":"2641_CR21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fphar.2018.00530","volume":"9","author":"CH Jiang","year":"2018","unstructured":"Jiang CH, Sun TL, Xiang DX, Wei SS, Li WQ. Anticancer activity and mechanism of xanthohumol: a prenylated flavonoid from hops (Humulus lupulus L.). Front Pharmacol. 2018;9:530. https:\/\/doi.org\/10.3389\/fphar.2018.00530.","journal-title":"Front Pharmacol"},{"issue":"1\u20132","key":"2641_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10555-012-9415-3","volume":"32","author":"Y Mao","year":"2013","unstructured":"Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32(1\u20132):303\u201315. https:\/\/doi.org\/10.1007\/s10555-012-9415-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2641_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/0008-5472.Can-15-1737","volume":"76","author":"CD Mills","year":"2016","unstructured":"Mills CD, Lenz LL, Harris RA. A breakthrough: macrophage-directed cancer immunotherapy. Can Res. 2016;76(3):513\u20136. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1737.","journal-title":"Can Res"},{"key":"2641_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030626","author":"E Malavasi","year":"2024","unstructured":"Malavasi E, Adamo M, Zamprogno E, Vella V, Giamas G, Gagliano T. Decoding the tumour microenvironment: molecular players, pathways, and therapeutic targets in cancer treatment. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16030626.","journal-title":"Cancers"},{"issue":"1","key":"2641_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62. https:\/\/doi.org\/10.1186\/s12935-020-01719-5.","journal-title":"Cancer Cell Int"},{"key":"2641_CR26","doi-asserted-by":"publisher","first-page":"16941","DOI":"10.1038\/srep16941","volume":"5","author":"KM McAndrews","year":"2015","unstructured":"McAndrews KM, McGrail DJ, Ravikumar N, Dawson MR. Mesenchymal stem cells induce directional migration of invasive breast cancer cells through TGF-\u03b2. Sci Rep. 2015;5:16941. https:\/\/doi.org\/10.1038\/srep16941.","journal-title":"Sci Rep"},{"issue":"6","key":"2641_CR27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.tice.2017.10.003","volume":"49","author":"A Do\u011fan","year":"2017","unstructured":"Do\u011fan A, Demirci S, Apdik H, Apdik EA, \u015eahin F. Dental pulp stem cells (DPSCs) increase prostate cancer cell proliferation and migration under in vitro conditions. Tissue Cell. 2017;49(6):711\u20138. https:\/\/doi.org\/10.1016\/j.tice.2017.10.003.","journal-title":"Tissue Cell"},{"issue":"31","key":"2641_CR28","doi-asserted-by":"publisher","first-page":"30472","DOI":"10.18632\/oncotarget.5401","volume":"6","author":"G Farnie","year":"2015","unstructured":"Farnie G, Sotgia F, Lisanti MP. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget. 2015;6(31):30472\u201386. https:\/\/doi.org\/10.18632\/oncotarget.5401.","journal-title":"Oncotarget"},{"key":"2641_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103028","author":"C Walker","year":"2018","unstructured":"Walker C, Mojares E, Del R\u00edo HA. Role of extracellular matrix in development and cancer progression. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19103028.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2641_CR30","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/sctm.17-0138","volume":"6","author":"F Papaccio","year":"2017","unstructured":"Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. 2017;6(12):2115\u201325. https:\/\/doi.org\/10.1002\/sctm.17-0138.","journal-title":"Stem Cells Transl Med"},{"key":"2641_CR31","doi-asserted-by":"publisher","first-page":"9620870","DOI":"10.1155\/2017\/9620870","volume":"2017","author":"KM Coyle","year":"2017","unstructured":"Coyle KM, Boudreau JE, Marcato P. Genetic mutations and epigenetic modifications: driving cancer and informing precision medicine. Biomed Res Int. 2017;2017:9620870. https:\/\/doi.org\/10.1155\/2017\/9620870.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2641_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tips.2020.01.001","volume":"41","author":"N Kozlova","year":"2020","unstructured":"Kozlova N, Grossman JE, Iwanicki MP, Muranen T. The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends Pharmacol Sci. 2020;41(3):183\u201398. https:\/\/doi.org\/10.1016\/j.tips.2020.01.001.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2641_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"issue":"2","key":"2641_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/imm.12036","volume":"138","author":"D Lindau","year":"2013","unstructured":"Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105\u201315. https:\/\/doi.org\/10.1111\/imm.12036.","journal-title":"Immunology"},{"key":"2641_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118110","volume":"258","author":"K Mortezaee","year":"2020","unstructured":"Mortezaee K. Immune escape: a critical hallmark in solid tumors. Life Sci. 2020;258: 118110. https:\/\/doi.org\/10.1016\/j.lfs.2020.118110.","journal-title":"Life Sci"},{"key":"2641_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2641_CR37","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313\u201325. https:\/\/doi.org\/10.1002\/jcp.27172.","journal-title":"J Cell Physiol"},{"issue":"18","key":"2641_CR38","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.Can-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Can Res. 2019;79(18):4557\u201366. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3962.","journal-title":"Can Res"},{"issue":"24","key":"2641_CR39","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1111\/febs.15776","volume":"288","author":"NK Karamanos","year":"2021","unstructured":"Karamanos NK, Theocharis AD, Piperigkou Z, Manou D, Passi A, Skandalis SS, et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288(24):6850\u2013912. https:\/\/doi.org\/10.1111\/febs.15776.","journal-title":"FEBS J"},{"issue":"12","key":"2641_CR40","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15(12):786\u2013801. https:\/\/doi.org\/10.1038\/nrm3904.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2641_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153. https:\/\/doi.org\/10.1038\/s41392-021-00544-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2641_CR42","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457\u201374. https:\/\/doi.org\/10.1038\/nrc.2017.51.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2641_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/ppo.0000000000000124","volume":"21","author":"HF Dvorak","year":"2015","unstructured":"Dvorak HF. Tumor stroma, tumor blood vessels, and antiangiogenesis therapy. Cancer J (Sudbury, Mass). 2015;21(4):237\u201343. https:\/\/doi.org\/10.1097\/ppo.0000000000000124.","journal-title":"Cancer J (Sudbury, Mass)"},{"issue":"1","key":"2641_CR44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-020-00966-3","volume":"13","author":"J L\u00f3pez de Andr\u00e9s","year":"2020","unstructured":"L\u00f3pez de Andr\u00e9s J, Gri\u00f1\u00e1n-Lis\u00f3n C, Jim\u00e9nez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136. https:\/\/doi.org\/10.1186\/s13045-020-00966-3.","journal-title":"J Hematol Oncol."},{"issue":"2","key":"2641_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10555-021-09968-0","volume":"40","author":"MA Nelson","year":"2021","unstructured":"Nelson MA, Ngamcherdtrakul W, Luoh SW, Yantasee W. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer Metastasis Rev. 2021;40(2):519\u201336. https:\/\/doi.org\/10.1007\/s10555-021-09968-0.","journal-title":"Cancer Metastasis Rev"},{"key":"2641_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136995","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22136995.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2641_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00262-005-0048-z","volume":"55","author":"S Kusmartsev","year":"2006","unstructured":"Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother CII. 2006;55(3):237\u201345. https:\/\/doi.org\/10.1007\/s00262-005-0048-z.","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"2641_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.2015.10.022","volume":"380","author":"P Qu","year":"2016","unstructured":"Qu P, Wang LZ, Lin PC. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Lett. 2016;380(1):253\u20136. https:\/\/doi.org\/10.1016\/j.canlet.2015.10.022.","journal-title":"Cancer Lett"},{"key":"2641_CR49","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","volume":"9","author":"C Fu","year":"2018","unstructured":"Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059. https:\/\/doi.org\/10.3389\/fimmu.2018.03059.","journal-title":"Front Immunol"},{"key":"2641_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.613492","volume":"12","author":"X Peng","year":"2021","unstructured":"Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of dendritic cells in tumor microenvironment: for immunotherapy. Front Immunol. 2021;12: 613492. https:\/\/doi.org\/10.3389\/fimmu.2021.613492.","journal-title":"Front Immunol"},{"key":"2641_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.003","volume":"343","author":"Z Liao","year":"2019","unstructured":"Liao Z, Tan ZW, Zhu P, Tan NS. Cancer-associated fibroblasts in tumor microenvironment - accomplices in tumor malignancy. Cell Immunol. 2019;343: 103729. https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.003.","journal-title":"Cell Immunol"},{"issue":"10","key":"2641_CR52","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1002\/ijc.25440","volume":"127","author":"K Shinagawa","year":"2010","unstructured":"Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer. 2010;127(10):2323\u201333. https:\/\/doi.org\/10.1002\/ijc.25440.","journal-title":"Int J Cancer"},{"key":"2641_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051272","author":"K Hida","year":"2018","unstructured":"Hida K, Maishi N, Annan DA, Hida Y. Contribution of tumor endothelial cells in cancer progression. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19051272.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2641_CR54","doi-asserted-by":"publisher","first-page":"eaat4758","DOI":"10.1126\/sciadv.aat4758","volume":"4","author":"Q Ma","year":"2018","unstructured":"Ma Q, Dieterich LC, Ikenberg K, Bachmann SB, Mangana J, Proulx ST, et al. Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread. Sci Adv. 2018;4(8):eaat4758. https:\/\/doi.org\/10.1126\/sciadv.aat4758.","journal-title":"Sci Adv"},{"key":"2641_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091433","author":"ES Fridman","year":"2022","unstructured":"Fridman ES, Ginini L, Gil Z. The role of extracellular vesicles in metabolic reprogramming of the tumor microenvironment. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11091433.","journal-title":"Cells"},{"issue":"1","key":"2641_CR56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1.","journal-title":"Signal Transduct Target Ther"},{"key":"2641_CR57","doi-asserted-by":"publisher","first-page":"114491","DOI":"10.1016\/j.biopha.2023.114491","volume":"161","author":"P Pandey","year":"2023","unstructured":"Pandey P, Khan F, Upadhyay TK, Seungjoon M, Park MN, Kim B. New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomed Pharmacother. 2023;161:114491. https:\/\/doi.org\/10.1016\/j.biopha.2023.114491.","journal-title":"Biomed Pharmacother"},{"issue":"Pt 2","key":"2641_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.semcancer.2022.03.028","volume":"86","author":"S Bose","year":"2022","unstructured":"Bose S, Saha P, Chatterjee B, Srivastava AK. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: Potential pharmacological targets for cancer therapy. Semin Cancer Biol. 2022;86(Pt 2):568\u201379. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.028.","journal-title":"Semin Cancer Biol"},{"issue":"20","key":"2641_CR59","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1042\/bcj20210233","volume":"479","author":"Q Wei","year":"2022","unstructured":"Wei Q, Task\u00e9n K. Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. Biochem J. 2022;479(20):2219\u201360. https:\/\/doi.org\/10.1042\/bcj20210233.","journal-title":"Biochem J"},{"issue":"1","key":"2641_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12964-022-00904-5","volume":"20","author":"J Gao","year":"2022","unstructured":"Gao J, Zhang X, Jiang L, Li Y, Zheng Q. Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling. Cell Commun Signal. 2022;20(1):97. https:\/\/doi.org\/10.1186\/s12964-022-00904-5.","journal-title":"Cell Commun Signal"},{"issue":"Pt 3","key":"2641_CR61","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.semcancer.2022.02.010","volume":"86","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Y, Ren Y, Zhang Q, Yi P, Cheng C. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Semin Cancer Biol. 2022;86(Pt 3):542\u201365. https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.010.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2641_CR62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ddr.21895","volume":"83","author":"S Hu","year":"2022","unstructured":"Hu S, Jiang S, Qi X, Bai R, Ye XY, Xie T. Races of small molecule clinical trials for the treatment of COVID-19: an up-to-date comprehensive review. Drug Dev Res. 2022;83(1):16\u201354. https:\/\/doi.org\/10.1002\/ddr.21895.","journal-title":"Drug Dev Res"},{"issue":"1","key":"2641_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101298","volume":"15","author":"X Lin","year":"2022","unstructured":"Lin X, Chen H, Xie Y, Zhou X, Wang Y, Zhou J, et al. Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer. Translat Oncol. 2022;15(1): 101298. https:\/\/doi.org\/10.1016\/j.tranon.2021.101298.","journal-title":"Translat Oncol"},{"issue":"4","key":"2641_CR64","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10555-015-9589-6","volume":"34","author":"M Garg","year":"2015","unstructured":"Garg M. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer. Cancer Metastasis Rev. 2015;34(4):691\u2013701. https:\/\/doi.org\/10.1007\/s10555-015-9589-6.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2641_CR65","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/jcp.21799","volume":"220","author":"HH Heng","year":"2009","unstructured":"Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol. 2009;220(3):538\u201347. https:\/\/doi.org\/10.1002\/jcp.21799.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2641_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"ER Malone","year":"2020","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. https:\/\/doi.org\/10.1186\/s13073-019-0703-1.","journal-title":"Genome Med"},{"issue":"1","key":"2641_CR67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134. https:\/\/doi.org\/10.1186\/s13045-019-0818-2.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2641_CR68","doi-asserted-by":"publisher","first-page":"14213","DOI":"10.1002\/jcb.28782","volume":"120","author":"S Hussain","year":"2019","unstructured":"Hussain S, Singh A, Nazir SU, Tulsyan S, Khan A, Kumar R, et al. Cancer drug resistance: a fleet to conquer. J Cell Biochem. 2019;120(9):14213\u201325. https:\/\/doi.org\/10.1002\/jcb.28782.","journal-title":"J Cell Biochem"},{"issue":"1","key":"2641_CR69","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","volume":"35","author":"MA Feitelson","year":"2015","unstructured":"Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Seminars Cancer Biol. 2015;35(1):S25\u201354. https:\/\/doi.org\/10.1016\/j.semcancer.2015.02.006.","journal-title":"Seminars Cancer Biol"},{"key":"2641_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med. 2015;13:45. https:\/\/doi.org\/10.1186\/s12916-015-0278-7.","journal-title":"BMC Med"},{"issue":"1","key":"2641_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59. https:\/\/doi.org\/10.1186\/s12964-020-0530-4.","journal-title":"Cell Commun Signal"},{"issue":"5","key":"2641_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/tan.12898","volume":"88","author":"B Seliger","year":"2016","unstructured":"Seliger B. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. Hla. 2016;88(5):213\u201320. https:\/\/doi.org\/10.1111\/tan.12898.","journal-title":"Hla"},{"issue":"4","key":"2641_CR73","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.Ccr-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(4):687\u201392. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-1860.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"Suppl 8","key":"2641_CR74","doi-asserted-by":"publisher","first-page":"viii8","DOI":"10.1093\/annonc\/mds256","volume":"23","author":"OJ Finn","year":"2012","unstructured":"Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(Suppl 8):viii8-9. https:\/\/doi.org\/10.1093\/annonc\/mds256.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2641_CR75","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.3389\/fimmu.2019.03070","volume":"10","author":"C Siret","year":"2019","unstructured":"Siret C, Collignon A, Silvy F, Robert S, Cheyrol T, Andr\u00e9 P, et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front Immunol. 2019;10:3070. https:\/\/doi.org\/10.3389\/fimmu.2019.03070.","journal-title":"Front Immunol"},{"key":"2641_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020210","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13020210.","journal-title":"Cancers"},{"issue":"1","key":"2641_CR77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2641_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cels.2023.03.004","volume":"14","author":"A Deshpande","year":"2023","unstructured":"Deshpande A, Loth M, Sidiropoulos DN, Zhang S, Yuan L, Bell ATF, et al. Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces. Cell Syst. 2023;14(4):285-301.e4. https:\/\/doi.org\/10.1016\/j.cels.2023.03.004.","journal-title":"Cell Syst"},{"key":"2641_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/0471143030.cb0322s30","author":"C Th\u00e9ry","year":"2006","unstructured":"Th\u00e9ry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protocols Cell Biol. 2006. https:\/\/doi.org\/10.1002\/0471143030.cb0322s30.","journal-title":"Curr Protocols Cell Biol"},{"issue":"4","key":"2641_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10544-016-0083-x","volume":"18","author":"MC Regier","year":"2016","unstructured":"Regier MC, Maccoux LJ, Weinberger EM, Regehr KJ, Berry SM, Beebe DJ, et al. Transitions from mono- to co- to tri-culture uniquely affect gene expression in breast cancer, stromal, and immune compartments. Biomed Microdevice. 2016;18(4):70. https:\/\/doi.org\/10.1007\/s10544-016-0083-x.","journal-title":"Biomed Microdevice"},{"key":"2641_CR81","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fbioe.2020.00907","volume":"8","author":"C Mondadori","year":"2020","unstructured":"Mondadori C, Crippa M, Moretti M, Candrian C, Lopa S, Arrigoni C. Advanced microfluidic models of cancer and immune cell extravasation: a systematic review of the literature. Front Bioeng Biotechnol. 2020;8:907. https:\/\/doi.org\/10.3389\/fbioe.2020.00907.","journal-title":"Front Bioeng Biotechnol"},{"key":"2641_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010181","author":"J Hoarau-V\u00e9chot","year":"2018","unstructured":"Hoarau-V\u00e9chot J, Rafii A, Touboul C, Pasquier J. Halfway between 2D and animal models: are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19010181.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2641_CR83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.lungcan.2009.12.005","volume":"68","author":"AF Gazdar","year":"2010","unstructured":"Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010;68(3):309\u201318. https:\/\/doi.org\/10.1016\/j.lungcan.2009.12.005.","journal-title":"Lung Cancer"},{"key":"2641_CR84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00455-2022","author":"MV Humbert","year":"2022","unstructured":"Humbert MV, Spalluto CM, Bell J, Blume C, Conforti F, Davies ER, et al. Towards an artificial human lung: modelling organ-like complexity to aid mechanistic understanding. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.00455-2022.","journal-title":"Eur Respir J"},{"issue":"5","key":"2641_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251132","volume":"16","author":"RA Helmer","year":"2021","unstructured":"Helmer RA, Martinez-Zaguilan R, Kaur G, Smith LA, Dufour JM, Chilton BS. Helicase-like transcription factor-deletion from the tumor microenvironment in a cell line-derived xenograft model of colorectal cancer reprogrammed the human transcriptome-S-nitroso-proteome to promote inflammation and redirect metastasis. PLoS ONE. 2021;16(5): e0251132. https:\/\/doi.org\/10.1371\/journal.pone.0251132.","journal-title":"PLoS ONE"},{"issue":"1","key":"2641_CR86","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"C-P Day","year":"2015","unstructured":"Day C-P, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39\u201353. https:\/\/doi.org\/10.1016\/j.cell.2015.08.068.","journal-title":"Cell"},{"issue":"50","key":"2641_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201901985","volume":"15","author":"KL Fetah","year":"2019","unstructured":"Fetah KL, DiPardo BJ, Kongadzem EM, Tomlinson JS, Elzagheid A, Elmusrati M, et al. Cancer modeling-on-a-chip with future artificial intelligence integration. Small. 2019;15(50): e1901985. https:\/\/doi.org\/10.1002\/smll.201901985.","journal-title":"Small"},{"issue":"9","key":"2641_CR88","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinsk\u00e1 E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0001.","journal-title":"Cancer Discov"},{"key":"2641_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121728","volume":"288","author":"LI Ibrahim","year":"2022","unstructured":"Ibrahim LI, Hajal C, Offeddu GS, Gillrie MR, Kamm RD. Omentum-on-a-chip: a multicellular, vascularized microfluidic model of the human peritoneum for the study of ovarian cancer metastases. Biomaterials. 2022;288: 121728. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121728.","journal-title":"Biomaterials"},{"issue":"1","key":"2641_CR90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32\u201342. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0013.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2641_CR91","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"2641_CR92","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59\u201370. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.05.002.","journal-title":"Oral Oncol"},{"key":"2641_CR93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.302","author":"M Zhang","year":"2020","unstructured":"Zhang M, Yang L, Fu X, Zhang L, Meng H, Li L, et al. First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma. Am Soc Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.302.","journal-title":"Am Soc Clin Oncol"},{"issue":"1","key":"2641_CR94","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s40425-019-0686-x","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7(1):202. https:\/\/doi.org\/10.1186\/s40425-019-0686-x.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2641_CR95","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-hodgkin\u2019s lymphomas. Mol Ther J Am Soc Gene Ther. 2018;26(12):2727\u201337. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.009.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"14","key":"2641_CR96","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. New Engl J Med. 2011;365(14):1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"New Engl J Med"},{"issue":"23","key":"2641_CR97","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","volume":"382","author":"V Minard-Colin","year":"2020","unstructured":"Minard-Colin V, Aup\u00e9rin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high-risk mature B-cell non-hodgkin\u2019s lymphoma in children. New Engl J Med. 2020;382(23):2207\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1915315.","journal-title":"New Engl J Med"},{"issue":"13_Supplement","key":"2641_CR98","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1158\/1538-7445.AM2017-3684","volume":"77","author":"R Woessner","year":"2017","unstructured":"Woessner R, Sah V, McCoon P, Grosskurth S, Deng N, DuPont R, et al. Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models. Cancer Res. 2017;77(13_Supplement):3684.","journal-title":"Cancer Res"},{"issue":"15_suupl","key":"2641_CR99","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1200\/JCO.2020.38.15_suppl.3064","volume":"38","author":"A Patnaik","year":"2020","unstructured":"Patnaik A, Spreafico A, Paterson AM, Peluso M, Chung J-K, Bowers B, et al. Results of a first-in-human phase I study of SRF231, a fully human, high-affinity anti-CD47 antibody. J Clin Oncol. 2020;38(15_suupl):3064. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.3064.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2641_CR100","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel M, O\u2019Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, et al. Phase 1b study of a small molecule antagonist of human chemokine (C\u2013C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38(3):800\u201311. https:\/\/doi.org\/10.1007\/s10637-019-00830-3.","journal-title":"Invest New Drugs"},{"issue":"5","key":"2641_CR101","first-page":"1639","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer1. Clin Cancer Res. 2003;9(5):1639\u201347.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2641_CR102","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/jco.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(19):3126\u201332. https:\/\/doi.org\/10.1200\/jco.2008.21.3223.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"2641_CR103","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1200\/jco.2005.05.013","volume":"23","author":"R Hoekstra","year":"2005","unstructured":"Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5188\u201397. https:\/\/doi.org\/10.1200\/jco.2005.05.013.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"2641_CR104","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1158\/1078-0432.CCR-06-1586","volume":"13","author":"AA Chiappori","year":"2007","unstructured":"Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, et al. A phase I pharmacokinetic and pharmacodynamic study of S-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007;13(7):2091\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1586.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2641_CR105","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1200\/JCO.2020.38.4_suppl.638","volume":"38","author":"MA Tempero","year":"2020","unstructured":"Tempero MA, Cutsem EV, Sigal D, Oh D-Y, Fazio N, Macarulla T, et al. HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel\/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA). J Clin Oncol. 2020;38(4):638. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.638.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2641_CR106","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/jco.2001.19.15.3447","volume":"19","author":"SR Bramhall","year":"2001","unstructured":"Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(15):3447\u201355. https:\/\/doi.org\/10.1200\/jco.2001.19.15.3447.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2641_CR107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12865-022-00514-3","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Zhao M, Hu Y, Guo H, Zhang Y, Huang Y, et al. Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer. BMC Immunol. 2022;23(1):37. https:\/\/doi.org\/10.1186\/s12865-022-00514-3.","journal-title":"BMC Immunol"},{"issue":"1","key":"2641_CR108","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14756366.2018.1532419","volume":"34","author":"E Andreucci","year":"2019","unstructured":"Andreucci E, Ruzzolini J, Peppicelli S, Bianchini F, Laurenzana A, Carta F, et al. The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019;34(1):117\u201323. https:\/\/doi.org\/10.1080\/14756366.2018.1532419.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"2641_CR109","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00280-016-3007-9","volume":"77","author":"F Zhao","year":"2016","unstructured":"Zhao F, Ming J, Zhou Y, Fan L. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother Pharmacol. 2016;77(5):963\u201372. https:\/\/doi.org\/10.1007\/s00280-016-3007-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"2641_CR110","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1158\/0008-5472.CAN-15-0108","volume":"75","author":"NV Rajeshkumar","year":"2015","unstructured":"Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Martinez GV, Le A, et al. Therapeutic targeting of the warburg effect in pancreatic cancer relies on an absence of p53 function. Can Res. 2015;75(16):3355\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0108.","journal-title":"Can Res"},{"issue":"1","key":"2641_CR111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbamem.2003.12.004","volume":"1661","author":"MT Travers","year":"2004","unstructured":"Travers MT, Gow IF, Barber MC, Thomson J, Shennan DB. Indoleamine 2,3-dioxygenase activity and l-tryptophan transport in human breast cancer cells. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2004;1661(1):106\u201312. https:\/\/doi.org\/10.1016\/j.bbamem.2003.12.004.","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes."},{"issue":"23","key":"2641_CR112","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1002\/cncr.30897","volume":"123","author":"MA Lowery","year":"2017","unstructured":"Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, et al. A phase 1\/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 2017;123(23):4556\u201365. https:\/\/doi.org\/10.1002\/cncr.30897.","journal-title":"Cancer"},{"issue":"6","key":"2641_CR113","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s11684-020-0804-7","volume":"15","author":"W Zhou","year":"2021","unstructured":"Zhou W, Zhang J, Yan M, Wu J, Lian S, Sun K, et al. Orlistat induces ferroptosis-like cell death of lung cancer cells. Front Med. 2021;15(6):922\u201332. https:\/\/doi.org\/10.1007\/s11684-020-0804-7.","journal-title":"Front Med"},{"issue":"5","key":"2641_CR114","first-page":"1410","volume":"62","author":"H Azuma","year":"2002","unstructured":"Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720. Mouse Breast Cancer Models Cancer Res. 2002;62(5):1410\u20139.","journal-title":"Mouse Breast Cancer Models Cancer Res"},{"issue":"21","key":"2641_CR115","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1038\/onc.2011.446","volume":"31","author":"C Gajate","year":"2012","unstructured":"Gajate C, Matos-da-Silva M, Dakir ELH, Fonteriz RI, Alvarez J, Mollinedo F. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene. 2012;31(21):2627\u201339. https:\/\/doi.org\/10.1038\/onc.2011.446.","journal-title":"Oncogene"},{"issue":"8","key":"2641_CR116","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","volume":"21","author":"B Besse","year":"2015","unstructured":"Besse B, Le Moulec S, Mazi\u00e8res J, Senellart H, Barlesi F, Chouaid C, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): A nonrandomized. Phase II Study Clin Cancer Res. 2015;21(8):1896\u2013903. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2082.","journal-title":"Phase II Study Clin Cancer Res"},{"key":"2641_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.965277","volume":"12","author":"A Cuypers","year":"2022","unstructured":"Cuypers A, Truong AK, Becker LM, Saavedra-Garc\u00eda P, Carmeliet P. Tumor vessel co-option: the past & the future. Front Oncol. 2022;12: 965277. https:\/\/doi.org\/10.3389\/fonc.2022.965277.","journal-title":"Front Oncol"},{"key":"2641_CR118","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3389\/fphar.2017.00952","volume":"8","author":"B Zhang","year":"2017","unstructured":"Zhang B, Hu Y, Pang Z. Modulating the tumor microenvironment to enhance tumor nanomedicine delivery. Front Pharmacol. 2017;8:952. https:\/\/doi.org\/10.3389\/fphar.2017.00952.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2641_CR119","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/stcltm\/szab001","volume":"11","author":"DJ Craig","year":"2022","unstructured":"Craig DJ, James AW, Wang Y, Tavian M, Crisan M, P\u00e9ault BM. Blood vessel resident human stem cells in health and disease. Stem Cells Transl Med. 2022;11(1):35\u201343. https:\/\/doi.org\/10.1093\/stcltm\/szab001.","journal-title":"Stem Cells Transl Med"},{"key":"2641_CR120","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.11.008","volume":"171","author":"D Ferland-McCollough","year":"2017","unstructured":"Ferland-McCollough D, Slater S, Richard J, Reni C, Mangialardi G. Pericytes, an overlooked player in vascular pathobiology. Pharmacol Ther. 2017;171:30\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.008.","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2641_CR121","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385. https:\/\/doi.org\/10.1038\/s12276-020-00500-y.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2641_CR122","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11(1):5120. https:\/\/doi.org\/10.1038\/s41467-020-18794-x.","journal-title":"Nat Commun"},{"issue":"1","key":"2641_CR123","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40880-017-0206-7","volume":"36","author":"C-N Qian","year":"2017","unstructured":"Qian C-N, Mei Y, Zhang J. Cancer metastasis: issues and challenges. Chin J Cancer. 2017;36(1):38. https:\/\/doi.org\/10.1186\/s40880-017-0206-7.","journal-title":"Chin J Cancer"},{"issue":"5","key":"2641_CR124","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/(sici)1097-0215(19990301)80:5<764::aid-ijc22>3.0.co;2-j","volume":"80","author":"JC Tonn","year":"1999","unstructured":"Tonn JC, Kerkau S, Hanke A, Bouterfa H, Mueller JG, Wagner S, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 1999;80(5):764\u201372. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990301)80:5%3c764::aid-ijc22%3e3.0.co;2-j.","journal-title":"Int J Cancer"},{"issue":"10","key":"2641_CR125","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10(10):753\u201368. https:\/\/doi.org\/10.2174\/187152010794728639.","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"2641_CR126","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth M-L, Carretta M, Kalvisa A, Siersb\u00e6k MS, et al. Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer. 2019;7(1):68. https:\/\/doi.org\/10.1186\/s40425-019-0556-6.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"2641_CR127","first-page":"5328","volume":"57","author":"B-H Jiang","year":"1997","unstructured":"Jiang B-H, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression1. Can Res. 1997;57(23):5328\u201335.","journal-title":"Can Res"},{"issue":"11","key":"2641_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201805955","volume":"31","author":"S Yang","year":"2019","unstructured":"Yang S, Tang Z, Hu C, Zhang D, Shen N, Yu H, et al. Selectively potentiating hypoxia levels by combretastatin A4 nanomedicine: toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors. Adv Mater (Deerfield Beach, Fla). 2019;31(11): e1805955. https:\/\/doi.org\/10.1002\/adma.201805955.","journal-title":"Adv Mater (Deerfield Beach, Fla)"},{"issue":"3","key":"2641_CR129","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/1078-0432.Ccr-11-1980","volume":"18","author":"JD Sun","year":"2012","unstructured":"Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(3):758\u201370. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-1980.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"2641_CR130","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-021-06332-2","volume":"189","author":"MCT Batenburg","year":"2021","unstructured":"Batenburg MCT, Maarse W, van der Leij F, Baas IO, Boonstra O, Lansdorp N, et al. The impact of hyperbaric oxygen therapy on late radiation toxicity and quality of life in breast cancer patients. Breast Cancer Res Treat. 2021;189(2):425\u201333. https:\/\/doi.org\/10.1007\/s10549-021-06332-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2641_CR131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li T, Qiao T. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Semin Cancer Biol. 2022;86:117\u201325. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.005.","journal-title":"Semin Cancer Biol"},{"key":"2641_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.01.004","volume":"296","author":"H Abumanhal-Masarweh","year":"2019","unstructured":"Abumanhal-Masarweh H, Koren L, Zinger A, Yaari Z, Krinsky N, Kaneti G, et al. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin. J Controll Releas Off J Controll Releas Soc. 2019;296:1\u201313. https:\/\/doi.org\/10.1016\/j.jconrel.2019.01.004.","journal-title":"J Controll Releas Off J Controll Releas Soc"},{"key":"2641_CR133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030569","author":"Z Benyahia","year":"2021","unstructured":"Benyahia Z, Blackman M, Hamelin L, Zampieri LX, Capeloa T, Bedin ML, et al. In vitro and in vivo characterization of MCT1 inhibitor AZD3965 confirms preclinical safety compatible with breast cancer treatment. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13030569.","journal-title":"Cancers"},{"key":"2641_CR134","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01008-1","author":"K Yagi","year":"2023","unstructured":"Yagi K, Maruo A, Ishida S, Aizawa F, Ushio S, Sakaguchi S, et al. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Clin Exp Med. 2023. https:\/\/doi.org\/10.1007\/s10238-023-01008-1.","journal-title":"Clin Exp Med"},{"key":"2641_CR135","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2021.11.024","volume":"341","author":"M Souri","year":"2022","unstructured":"Souri M, Soltani M, Moradi Kashkooli F, Kiani SM. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. J Control Release. 2022;341:227\u201346. https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.024.","journal-title":"J Control Release"},{"issue":"8","key":"2641_CR136","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.7150\/jca.70725","volume":"13","author":"H Huang","year":"2022","unstructured":"Huang H, Zhu G, Shi R, Li Y, Zhang Z, Xu S, et al. Development and validation of a combined hypoxia and immune prognostic classifier for lung adenocarcinoma. J Cancer. 2022;13(8):2631\u201343. https:\/\/doi.org\/10.7150\/jca.70725.","journal-title":"J Cancer"},{"issue":"1","key":"2641_CR137","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2121-15-16","volume":"15","author":"J Jia","year":"2014","unstructured":"Jia J, Martin TA, Ye L, Jiang WG. FAP-\u03b1 (Fibroblast activation protein-\u03b1) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 2014;15(1):16. https:\/\/doi.org\/10.1186\/1471-2121-15-16.","journal-title":"BMC Cell Biol"},{"issue":"25","key":"2641_CR138","doi-asserted-by":"publisher","first-page":"21614","DOI":"10.18632\/oncotarget.4308","volume":"6","author":"M Serova","year":"2015","unstructured":"Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget. 2015;6(25):21614\u201327. https:\/\/doi.org\/10.18632\/oncotarget.4308.","journal-title":"Oncotarget"},{"key":"2641_CR139","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.imlet.2019.03.004","volume":"208","author":"F Vahidian","year":"2019","unstructured":"Vahidian F, Duijf PHG, Safarzadeh E, Derakhshani A, Baghbanzadeh A, Baradaran B. Interactions between cancer stem cells, immune system and some environmental components: friends or foes? Immunol Lett. 2019;208:19\u201329. https:\/\/doi.org\/10.1016\/j.imlet.2019.03.004.","journal-title":"Immunol Lett"},{"issue":"5","key":"2641_CR140","doi-asserted-by":"publisher","first-page":"598","DOI":"10.37349\/etat.2022.00103","volume":"3","author":"J Thiery","year":"2022","unstructured":"Thiery J. Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. Explor Target Anti-tumor Ther. 2022;3(5):598\u2013629. https:\/\/doi.org\/10.37349\/etat.2022.00103.","journal-title":"Explor Target Anti-tumor Ther"},{"key":"2641_CR141","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jconrel.2016.09.014","volume":"241","author":"B Chen","year":"2016","unstructured":"Chen B, Dai W, Mei D, Liu T, Li S, He B, et al. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J Control Release. 2016;241:68\u201380. https:\/\/doi.org\/10.1016\/j.jconrel.2016.09.014.","journal-title":"J Control Release"},{"issue":"41","key":"2641_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202308413","volume":"62","author":"W Chen","year":"2023","unstructured":"Chen W, Li Y, Liu C, Kang Y, Qin D, Chen S, et al. In situ Engineering of tumor-associated macrophages via a nanodrug-delivering-drug (\u03b2-Elemene@Stanene) strategy for enhanced cancer chemo-immunotherapy. Angew Chem Int Ed. 2023;62(41): e202308413. https:\/\/doi.org\/10.1002\/anie.202308413.","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"2641_CR143","doi-asserted-by":"publisher","first-page":"789","DOI":"10.7150\/thno.18133","volume":"7","author":"P Li","year":"2017","unstructured":"Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation techniques. Theranostics. 2017;7(3):789\u2013804. https:\/\/doi.org\/10.7150\/thno.18133.","journal-title":"Theranostics"},{"key":"2641_CR144","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jconrel.2020.07.042","volume":"326","author":"S Salunkhe","year":"2020","unstructured":"Salunkhe S, Dheeraj Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Controll Releas. 2020;326:599\u2013614. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.042.","journal-title":"J Controll Releas"},{"key":"2641_CR145","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.addr.2021.04.027","volume":"174","author":"D Buschmann","year":"2021","unstructured":"Buschmann D, Mussack V, Byrd JB. Separation, characterization, and standardization of extracellular vesicles for drug delivery applications. Adv Drug Deliv Rev. 2021;174:348\u201368. https:\/\/doi.org\/10.1016\/j.addr.2021.04.027.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2641_CR146","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.7150\/thno.64805","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, Kshirsagar PG, Gautam SK, Gulati M, Wafa EI, Christiansen JC, et al. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics. 2022;12(3):1030\u201360. https:\/\/doi.org\/10.7150\/thno.64805.","journal-title":"Theranostics"},{"issue":"51","key":"2641_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002440","volume":"32","author":"GH Nam","year":"2020","unstructured":"Nam GH, Choi Y, Kim GB, Kim S, Kim SA, Kim IS. Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater (Deerfield Beach, Fla). 2020;32(51): e2002440. https:\/\/doi.org\/10.1002\/adma.202002440.","journal-title":"Adv Mater (Deerfield Beach, Fla)"},{"issue":"2","key":"2641_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10284","volume":"7","author":"H Huang","year":"2022","unstructured":"Huang H, Shao L, Chen Y, Tang L, Liu T, Li J, et al. Synergistic strategy with hyperthermia therapy based immunotherapy and engineered exosomes-liposomes targeted chemotherapy prevents tumor recurrence and metastasis in advanced breast cancer. Bioeng Transl Med. 2022;7(2): e10284. https:\/\/doi.org\/10.1002\/btm2.10284.","journal-title":"Bioeng Transl Med"},{"key":"2641_CR149","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000875","author":"KM McAndrews","year":"2021","unstructured":"McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci Alliance. 2021. https:\/\/doi.org\/10.26508\/lsa.202000875.","journal-title":"Life Sci Alliance"},{"issue":"2","key":"2641_CR150","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ymthe.2021.10.012","volume":"30","author":"X Hu","year":"2022","unstructured":"Hu X, Shen N, Liu A, Wang W, Zhang L, Sui Z, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins. Mol Ther. 2022;30(2):763\u201381. https:\/\/doi.org\/10.1016\/j.ymthe.2021.10.012.","journal-title":"Mol Ther"},{"issue":"1","key":"2641_CR151","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1002\/mog2.66","volume":"3","author":"OS Sahoo","year":"2024","unstructured":"Sahoo OS, Mitra R, Nagaiah NKH. The hidden architects of glioblastoma multiforme: glioma stem cells. MedComm Oncol. 2024;3(1):e66. https:\/\/doi.org\/10.1002\/mog2.66.","journal-title":"MedComm Oncol"},{"issue":"23","key":"2641_CR152","doi-asserted-by":"publisher","first-page":"2100088","DOI":"10.1002\/adfm.202100088","volume":"31","author":"Z Li","year":"2021","unstructured":"Li Z, Wang Y, Ding Y, Repp L, Kwon GS, Hu Q. Cell-based delivery systems: emerging carriers for immunotherapy. Adv Funct Mater. 2021;31(23):2100088. https:\/\/doi.org\/10.1002\/adfm.202100088.","journal-title":"Adv Funct Mater"},{"issue":"3","key":"2641_CR153","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1586\/14737140.5.3.537","volume":"5","author":"A Delcayre","year":"2005","unstructured":"Delcayre A, Shu H, Le Pecq J-B. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature\u2019s antigen delivery pathway. Expert Rev Anticancer Ther. 2005;5(3):537\u201347. https:\/\/doi.org\/10.1586\/14737140.5.3.537.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2641_CR154","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/187152008783961932","volume":"8","author":"M Lopez-Lazaro","year":"2008","unstructured":"Lopez-Lazaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anti-Cancer Agents Med Chem Anti-Cancer Agents. 2008;8(3):305\u201312. https:\/\/doi.org\/10.2174\/187152008783961932.","journal-title":"Anti-Cancer Agents Med Chem Anti-Cancer Agents"},{"issue":"8","key":"2641_CR155","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","volume":"11","author":"Y Liu","year":"2012","unstructured":"Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A Small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11(8):1672\u201382. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0131.","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"2641_CR156","doi-asserted-by":"publisher","first-page":"7986","DOI":"10.1158\/0008-5472.CAN-09-2266","volume":"69","author":"C Yang","year":"2009","unstructured":"Yang C, Sudderth J, Dang T, Bachoo RG, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or akt signaling. Can Res. 2009;69(20):7986\u201393. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2266.","journal-title":"Can Res"},{"issue":"9","key":"2641_CR157","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.cellsig.2014.03.020","volume":"26","author":"P Yang","year":"2014","unstructured":"Yang P, Li Z, Fu R, Wu H, Li Z. Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell Signal. 2014;26(9):1853\u201362. https:\/\/doi.org\/10.1016\/j.cellsig.2014.03.020.","journal-title":"Cell Signal"},{"key":"2641_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091372","author":"GH Mohammad","year":"2019","unstructured":"Mohammad GH, Vassileva V, Acedo P, Olde Damink SWM, Malago M, Dhar DK, et al. Targeting pyruvate kinase M2 and lactate dehydrogenase a is an effective combination strategy for the treatment of pancreatic cancer. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091372.","journal-title":"Cancers."},{"issue":"3","key":"2641_CR159","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/cas.15649","volume":"114","author":"E Yang","year":"2023","unstructured":"Yang E, Wang X, Huang S, Li M, Li Y, Geng Y, et al. Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction. Cancer Sci. 2023;114(3):806\u201321. https:\/\/doi.org\/10.1111\/cas.15649.","journal-title":"Cancer Sci"},{"key":"2641_CR160","doi-asserted-by":"publisher","DOI":"10.4172\/2476-2261.1000129","author":"RS Wahdan-Alaswad","year":"2018","unstructured":"Wahdan-Alaswad RS, Edgerton SM, Salem HS, Thor AD. Metformin targets glucose metabolism in triple negative breast cancer. J Oncol Transl Res. 2018. https:\/\/doi.org\/10.4172\/2476-2261.1000129.","journal-title":"J Oncol Transl Res"},{"key":"2641_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176156","author":"S Br\u00f6er","year":"2020","unstructured":"Br\u00f6er S. Amino acid transporters as targets for cancer therapy: why, where, when, and how. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21176156.","journal-title":"Int J Mol Sci."},{"issue":"12","key":"2641_CR162","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/ijc.25202","volume":"126","author":"B Delage","year":"2010","unstructured":"Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762\u201372. https:\/\/doi.org\/10.1002\/ijc.25202.","journal-title":"Int J Cancer"},{"issue":"1","key":"2641_CR163","doi-asserted-by":"publisher","first-page":"11253","DOI":"10.1038\/s41598-017-10542-4","volume":"7","author":"H-J Tsai","year":"2017","unstructured":"Tsai H-J, Jiang SS, Hung W-C, Borthakur G, Lin S-F, Pemmaraju N, et al. A phase II study of arginine deiminase (ADI-PEG20) in relapsed\/refractory or poor-risk acute myeloid leukemia patients. Sci Rep. 2017;7(1):11253. https:\/\/doi.org\/10.1038\/s41598-017-10542-4.","journal-title":"Sci Rep"},{"issue":"1","key":"2641_CR164","doi-asserted-by":"publisher","first-page":"16776","DOI":"10.1038\/s41598-019-53397-7","volume":"9","author":"K Higuchi","year":"2019","unstructured":"Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, et al. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci Rep. 2019;9(1):16776. https:\/\/doi.org\/10.1038\/s41598-019-53397-7.","journal-title":"Sci Rep"},{"key":"2641_CR165","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fchem.2018.00392","volume":"6","author":"G Rao","year":"2018","unstructured":"Rao G, Nkepang G, Xu J, Yari H, Houson H, Teng C, et al. Ubiquitin receptor RPN13 mediates the inhibitory interaction of diphenyldihaloketones CLEFMA and EF24 with the 26S proteasome. Front Chem. 2018;6:392. https:\/\/doi.org\/10.3389\/fchem.2018.00392.","journal-title":"Front Chem"},{"key":"2641_CR166","first-page":"127","volume-title":"Genomics and pharmacogenomics in anticancer drug development and clinical response","author":"MR Litzow","year":"2009","unstructured":"Litzow MR. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients. In: Innocenti F, editor. Genomics and pharmacogenomics in anticancer drug development and clinical response. Totowa: Humana Press; 2009. p. 127\u201350."},{"issue":"8","key":"2641_CR167","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/cam4.761","volume":"5","author":"DE Peterson","year":"2016","unstructured":"Peterson DE, O\u2019Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897\u2013907. https:\/\/doi.org\/10.1002\/cam4.761.","journal-title":"Cancer Med"},{"key":"2641_CR168","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.semcancer.2016.09.001","volume":"40\u201341","author":"PR Dandawate","year":"2016","unstructured":"Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol. 2016;40\u201341:192\u2013208. https:\/\/doi.org\/10.1016\/j.semcancer.2016.09.001.","journal-title":"Semin Cancer Biol"},{"key":"2641_CR169","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3389\/fonc.2019.01412","volume":"9","author":"L Che","year":"2019","unstructured":"Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, prognostic, and therapeutic role of fatty acid synthase in human hepatocellular carcinoma. Front Oncol. 2019;9:1412. https:\/\/doi.org\/10.3389\/fonc.2019.01412.","journal-title":"Front Oncol"},{"issue":"6","key":"2641_CR170","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138920106779116928","volume":"7","author":"R Lupu","year":"2006","unstructured":"Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol. 2006;7(6):483\u201394. https:\/\/doi.org\/10.2174\/138920106779116928.","journal-title":"Curr Pharm Biotechnol"},{"key":"2641_CR171","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2017.05.002","volume":"401","author":"Q Liu","year":"2017","unstructured":"Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.002.","journal-title":"Cancer Lett"},{"key":"2641_CR172","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.phrs.2018.11.020","volume":"139","author":"J Skoda","year":"2019","unstructured":"Skoda J, Borankova K, Jansson PJ, Huang MLH, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: an ancient organelle at the crossroad of novel anti-cancer therapies. Pharmacol Res. 2019;139:298\u2013313. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.020.","journal-title":"Pharmacol Res"},{"issue":"7","key":"2641_CR173","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41374-021-00583-9","volume":"101","author":"A Morales","year":"2021","unstructured":"Morales A, Greenberg M, Nardi F, Gil V, Hayward SW, Crawford SE, et al. Loss of ephrin B2 receptor (EPHB2) sets lipid rheostat by regulating proteins DGAT1 and ATGL inducing lipid droplet storage in prostate cancer cells. Lab Invest. 2021;101(7):921\u201334. https:\/\/doi.org\/10.1038\/s41374-021-00583-9.","journal-title":"Lab Invest"},{"key":"2641_CR174","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1051\/vcm\/2023006","volume":"4","author":"Y Mei","year":"2023","unstructured":"Mei Y, Wang J, Lu J-B, Lu G-M, Peng L-X, Lang Y-H, et al. Loss of monoacylglycerol O-acyltransferase 2 can be compensated for by diacylglycerol O-acyltransferases 1 and 2 resulting in a negligible influence on mammary cancer development found in a mouse model and verified in human tissues. Vis Cancer Med. 2023;4:9.","journal-title":"Vis Cancer Med"},{"issue":"10","key":"2641_CR175","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/1541-7786.MCR-18-1343","volume":"17","author":"MJ VandeKopple","year":"2019","unstructured":"VandeKopple MJ, Wu J, Auer EN, Giaccia AJ, Denko NC, Papandreou I. HILPDA regulates lipid metabolism, lipid droplet abundance, and response to microenvironmental stress in solid tumors. Mol Cancer Res. 2019;17(10):2089\u2013101. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-1343.","journal-title":"Mol Cancer Res"},{"key":"2641_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/jcm5020015","author":"D D\u2019Eliseo","year":"2016","unstructured":"D\u2019Eliseo D, Velotti F. Omega-3 fatty acids and cancer cell cytotoxicity: implications for multi-targeted cancer therapy. J Clin Med. 2016. https:\/\/doi.org\/10.3390\/jcm5020015.","journal-title":"J Clin Med"},{"key":"2641_CR177","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s40610-017-0073-7","volume":"3","author":"F Runa","year":"2017","unstructured":"Runa F, Hamalian S, Meade K, Shisgal P, Gray P, Kelber JJ. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep. 2017;3:218\u201329.","journal-title":"Curr Mol Biol Rep"},{"issue":"1","key":"2641_CR178","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","volume":"18","author":"A Lin","year":"2019","unstructured":"Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019;18(1):139. https:\/\/doi.org\/10.1186\/s12943-019-1062-7.","journal-title":"Mol Cancer"},{"issue":"1","key":"2641_CR179","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-019-1047-6","volume":"18","author":"C Lu","year":"2019","unstructured":"Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer. 2019;18(1):130. https:\/\/doi.org\/10.1186\/s12943-019-1047-6.","journal-title":"Mol Cancer"},{"key":"2641_CR180","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2020.00397","volume":"10","author":"S Brassart-Pasco","year":"2020","unstructured":"Brassart-Pasco S, Br\u00e9zillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020;10:397. https:\/\/doi.org\/10.3389\/fonc.2020.00397.","journal-title":"Front Oncol"},{"issue":"1","key":"2641_CR181","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157. https:\/\/doi.org\/10.1186\/s12943-019-1089-9.","journal-title":"Mol Cancer"},{"issue":"2","key":"2641_CR182","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1073\/pnas.1904022116","volume":"117","author":"JH Newman","year":"2020","unstructured":"Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, et al. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci USA. 2020;117(2):1119\u201328. https:\/\/doi.org\/10.1073\/pnas.1904022116.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2641_CR183","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. https:\/\/doi.org\/10.3389\/fimmu.2019.00168.","journal-title":"Front Immunol"},{"key":"2641_CR184","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu D, Ciecielski KJ, Ruess DA, Alg\u00fcl H. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front Immunol. 2018;9:1878. https:\/\/doi.org\/10.3389\/fimmu.2018.01878.","journal-title":"Front Immunol"},{"issue":"1","key":"2641_CR185","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","volume":"37","author":"R Tamura","year":"2019","unstructured":"Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol (Northwood, London, England). 2019;37(1):2. https:\/\/doi.org\/10.1007\/s12032-019-1329-2.","journal-title":"Med Oncol (Northwood, London, England)"},{"issue":"7","key":"2641_CR186","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/mc.23179","volume":"59","author":"RJ Torphy","year":"2020","unstructured":"Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog. 2020;59(7):775\u201382. https:\/\/doi.org\/10.1002\/mc.23179.","journal-title":"Mol Carcinog"},{"issue":"7","key":"2641_CR187","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523\u201345. https:\/\/doi.org\/10.1016\/j.it.2022.04.010.","journal-title":"Trends Immunol"},{"key":"2641_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9020138","author":"S Rameshbabu","year":"2021","unstructured":"Rameshbabu S, Labadie BW, Argulian A, Patnaik A. Targeting innate immunity in cancer therapy. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9020138.","journal-title":"Vaccines."},{"issue":"3","key":"2641_CR189","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","journal-title":"Nat Rev Drug Discovery"},{"issue":"8","key":"2641_CR190","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1078-0432.Ccr-16-0049","volume":"22","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(8):1845\u201355. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0049.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"2641_CR191","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2(6):286\u201394. https:\/\/doi.org\/10.1016\/j.trecan.2016.05.002.","journal-title":"Trends Cancer"},{"issue":"6","key":"2641_CR192","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.cell.2010.02.015","volume":"140","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798\u2013804. https:\/\/doi.org\/10.1016\/j.cell.2010.02.015.","journal-title":"Cell"},{"issue":"22","key":"2641_CR193","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2022;9(22):e2201734. https:\/\/doi.org\/10.1002\/advs.202201734.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"11","key":"2641_CR194","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2326-6066.Cir-16-0177","volume":"4","author":"EJ Brea","year":"2016","unstructured":"Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, et al. Kinase regulation of human MHC class I molecule expression on cancer cells. Cancer Immunol Res. 2016;4(11):936\u201347. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0177.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2641_CR195","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738. https:\/\/doi.org\/10.1038\/s41467-017-01460-0.","journal-title":"Nat Commun"},{"key":"2641_CR196","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol. 2016;3:16015. https:\/\/doi.org\/10.1038\/mto.2016.15.","journal-title":"Mol Ther Oncol"},{"issue":"9","key":"2641_CR197","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discovery. 2015;14(9):642\u201362. https:\/\/doi.org\/10.1038\/nrd4663.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"2641_CR198","doi-asserted-by":"publisher","first-page":"19","DOI":"10.21037\/cco.2017.02.04","volume":"6","author":"A Patel","year":"2017","unstructured":"Patel A, Kaufman HL, Disis ML. Next generation approaches for tumor vaccination. Chin Clin Oncol. 2017;6(2):19. https:\/\/doi.org\/10.21037\/cco.2017.02.04.","journal-title":"Chin Clin Oncol"},{"key":"2641_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194562","author":"A Ashrafi","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, et al. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14194562.","journal-title":"Cancers"},{"key":"2641_CR200","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12935-018-0538-7","volume":"18","author":"K Lohitesh","year":"2018","unstructured":"Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44. https:\/\/doi.org\/10.1186\/s12935-018-0538-7.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2641_CR201","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","volume":"269","author":"JS Carew","year":"2008","unstructured":"Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.037.","journal-title":"Cancer Lett"},{"issue":"7","key":"2641_CR202","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679\u201392. https:\/\/doi.org\/10.1038\/nbt.2284.","journal-title":"Nat Biotechnol"},{"issue":"1\u20132","key":"2641_CR203","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"GR Zimmermann","year":"2007","unstructured":"Zimmermann GR, Leh\u00e1r J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today. 2007;12(1\u20132):34\u201342. https:\/\/doi.org\/10.1016\/j.drudis.2006.11.008.","journal-title":"Drug Discovery Today"},{"issue":"5","key":"2641_CR204","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744\u201350. https:\/\/doi.org\/10.1038\/s41591-019-0407-5.","journal-title":"Nat Med"},{"issue":"1","key":"2641_CR205","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discovery. 2020;19(1):39\u201356. https:\/\/doi.org\/10.1038\/s41573-019-0044-1.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"2641_CR206","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cas.12366","volume":"105","author":"N Hosoya","year":"2014","unstructured":"Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105(4):370\u201388. https:\/\/doi.org\/10.1111\/cas.12366.","journal-title":"Cancer Sci"},{"key":"2641_CR207","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040840","author":"C Roma-Rodrigues","year":"2019","unstructured":"Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20040840.","journal-title":"Int J Mol Sci."},{"key":"2641_CR208","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2014.12.018","volume":"201","author":"IA Khawar","year":"2015","unstructured":"Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Controll Releas Off J Controll Releas Soc. 2015;201:78\u201389. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.018.","journal-title":"J Controll Releas Off J Controll Releas Soc"},{"issue":"3","key":"2641_CR209","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143\u201358. https:\/\/doi.org\/10.1038\/nrclinonc.2015.209.","journal-title":"Nat Rev Clin Oncol"},{"key":"2641_CR210","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061188","author":"IT Chyuan","year":"2021","unstructured":"Chyuan IT, Chu CL, Hsu PN. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13061188.","journal-title":"Cancers."},{"issue":"4","key":"2641_CR211","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.drudis.2021.11.015","volume":"27","author":"Y Fu","year":"2022","unstructured":"Fu Y, Saraswat AL, Monpara J, Patel K. Stromal disruption facilitating invasion of a \u2018nano-arsenal\u2019 into the solid tumor. Drug Discovery Today. 2022;27(4):1132\u201341. https:\/\/doi.org\/10.1016\/j.drudis.2021.11.015.","journal-title":"Drug Discovery Today"},{"issue":"11","key":"2641_CR212","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2217\/nnm.16.37","volume":"11","author":"K Patel","year":"2016","unstructured":"Patel K, Doddapaneni R, Chowdhury N, Boakye CH, Behl G, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond). 2016;11(11):1377\u201392. https:\/\/doi.org\/10.2217\/nnm.16.37.","journal-title":"Nanomedicine (Lond)"},{"key":"2641_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100718","volume":"53","author":"E P\u00e9rez-Ruiz","year":"2020","unstructured":"P\u00e9rez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, Garc\u00eda-Aranda M, De Las RJ. Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resist Updates Rev Comment Antimicrobial Anticancer Chemother. 2020;53: 100718. https:\/\/doi.org\/10.1016\/j.drup.2020.100718.","journal-title":"Drug Resist Updates Rev Comment Antimicrobial Anticancer Chemother"},{"issue":"1","key":"2641_CR214","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6\u201323. https:\/\/doi.org\/10.1111\/imr.12766.","journal-title":"Immunol Rev"},{"issue":"1","key":"2641_CR215","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75. https:\/\/doi.org\/10.1038\/s41392-021-00484-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2641_CR216","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jso.24642","volume":"116","author":"RA Skelton","year":"2017","unstructured":"Skelton RA, Javed A, Zheng L, He J. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. J Surg Oncol. 2017;116(1):55\u201362. https:\/\/doi.org\/10.1002\/jso.24642.","journal-title":"J Surg Oncol"},{"issue":"7","key":"2641_CR217","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mc.23183","volume":"59","author":"H Ruan","year":"2020","unstructured":"Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic cell death in colon cancer prevention and therapy. Mol Carcinog. 2020;59(7):783\u201393. https:\/\/doi.org\/10.1002\/mc.23183.","journal-title":"Mol Carcinog"},{"issue":"2","key":"2641_CR218","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nbt0206-163","volume":"24","author":"D Lane","year":"2006","unstructured":"Lane D. Designer combination therapy for cancer. Nat Biotechnol. 2006;24(2):163\u20134. https:\/\/doi.org\/10.1038\/nbt0206-163.","journal-title":"Nat Biotechnol"},{"key":"2641_CR219","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med"},{"issue":"10","key":"2641_CR220","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/cam4.1124","volume":"6","author":"H Kitano","year":"2017","unstructured":"Kitano H, Kitadai Y, Teishima J, Yuge R, Shinmei S, Goto K, et al. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma. Cancer Med. 2017;6(10):2308\u201320. https:\/\/doi.org\/10.1002\/cam4.1124.","journal-title":"Cancer Med"},{"key":"2641_CR221","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1479-5876-5-38","volume":"5","author":"DP Mangiameli","year":"2007","unstructured":"Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, et al. Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med. 2007;5:38. https:\/\/doi.org\/10.1186\/1479-5876-5-38.","journal-title":"J Transl Med"},{"key":"2641_CR222","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010037","author":"H Huang","year":"2022","unstructured":"Huang H, Huang F, Liang X, Fu Y, Cheng Z, Huang Y, et al. Afatinib Reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma. Pharmaceuticals (Basel, Switzerland). 2022. https:\/\/doi.org\/10.3390\/ph16010037.","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"4","key":"2641_CR223","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14489","volume":"30","author":"WW Duan","year":"2024","unstructured":"Duan WW, Yang LT, Liu J, Dai ZY, Wang ZY, Zhang H, et al. A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther. 2024;30(4): e14489. https:\/\/doi.org\/10.1111\/cns.14489.","journal-title":"CNS Neurosci Ther"},{"key":"2641_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119513","volume":"585","author":"Y Nie","year":"2020","unstructured":"Nie Y, Li D, Peng Y, Wang S, Hu S, Liu M, et al. Metal organic framework coated MnO(2) nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm. 2020;585: 119513. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119513.","journal-title":"Int J Pharm"},{"issue":"4","key":"2641_CR225","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17(4):251\u201366. https:\/\/doi.org\/10.1038\/s41571-019-0308-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2641_CR226","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.31069","volume":"142","author":"S Rodic","year":"2018","unstructured":"Rodic S, Vincent MD. Reactive oxygen species (ROS) are a key determinant of cancer\u2019s metabolic phenotype. Int J Cancer. 2018;142(3):440\u20138. https:\/\/doi.org\/10.1002\/ijc.31069.","journal-title":"Int J Cancer"},{"issue":"8","key":"2641_CR227","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1089\/ars.2011.4367","volume":"19","author":"LL Policastro","year":"2013","unstructured":"Policastro LL, Iba\u00f1ez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal. 2013;19(8):854\u201395. https:\/\/doi.org\/10.1089\/ars.2011.4367.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"2641_CR228","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41563-020-0669-9","volume":"19","author":"I de L\u00e1zaro","year":"2020","unstructured":"de L\u00e1zaro I, Mooney DJ. A nanoparticle\u2019s pathway into tumours. Nat Mater. 2020;19(5):486\u20137. https:\/\/doi.org\/10.1038\/s41563-020-0669-9.","journal-title":"Nat Mater"},{"key":"2641_CR229","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13060840","author":"SI Bukhari","year":"2021","unstructured":"Bukhari SI, Imam SS, Ahmad MZ, Vuddanda PR, Alshehri S, Mahdi WA, et al. Recent progress in lipid nanoparticles for cancer theranostics: opportunity and challenges. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13060840.","journal-title":"Pharmaceutics."},{"issue":"11","key":"2641_CR230","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.apsb.2020.08.010","volume":"10","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Yu X, Thamphiwatana SD, Zheng Y, Pang Z. Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. Acta Pharmaceutica Sinica B. 2020;10(11):2054\u201374. https:\/\/doi.org\/10.1016\/j.apsb.2020.08.010.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2641_CR231","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.addr.2020.06.025","volume":"163\u2013164","author":"F Soetaert","year":"2020","unstructured":"Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies. Adv Drug Deliv Rev. 2020;163\u2013164:65\u201383. https:\/\/doi.org\/10.1016\/j.addr.2020.06.025.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"2641_CR232","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.cclet.2020.11.006","volume":"32","author":"J Hu","year":"2021","unstructured":"Hu J, Yuan X, Wang F, Gao H, Liu X, Zhang W. The progress and perspective of strategies to improve tumor penetration of nanomedicines. Chin Chem Lett. 2021;32(4):1341\u20137. https:\/\/doi.org\/10.1016\/j.cclet.2020.11.006.","journal-title":"Chin Chem Lett"},{"issue":"11","key":"2641_CR233","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nmat3792","volume":"12","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958\u201362. https:\/\/doi.org\/10.1038\/nmat3792.","journal-title":"Nat Mater"},{"issue":"11","key":"2641_CR234","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.apsb.2020.05.008","volume":"10","author":"J Li","year":"2020","unstructured":"Li J, Burgess DJ. Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. Acta Pharmaceutica Sinica B. 2020;10(11):2110\u201324. https:\/\/doi.org\/10.1016\/j.apsb.2020.05.008.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2641_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101240","volume":"40","author":"S Peng","year":"2021","unstructured":"Peng S, Wang H, Xin Y, Zhao W, Zhan M, Li J, et al. Second near-infrared photoactivatable hydrogen selenide nanogenerators for metastasis-inhibited cancer therapy. Nano Today. 2021;40: 101240. https:\/\/doi.org\/10.1016\/j.nantod.2021.101240.","journal-title":"Nano Today"},{"issue":"1","key":"2641_CR236","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41565-020-00817-9","volume":"16","author":"W Jiang","year":"2021","unstructured":"Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021;16(1):6\u201315. https:\/\/doi.org\/10.1038\/s41565-020-00817-9.","journal-title":"Nat Nanotechnol"},{"key":"2641_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2020.101073","volume":"37","author":"H Sun","year":"2021","unstructured":"Sun H, Zhang Q, Li J, Peng S, Wang X, Cai RJNT. Near-infrared photoactivated nanomedicines for photothermal synergistic cancer therapy. Nanotoday. 2021;37: 101073.","journal-title":"Nanotoday"},{"issue":"8","key":"2641_CR238","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41565-018-0146-7","volume":"13","author":"CS Chiang","year":"2018","unstructured":"Chiang CS, Lin YJ, Lee R, Lai YH, Cheng HW, Hsieh CH, et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nat Nanotechnol. 2018;13(8):746\u201354. https:\/\/doi.org\/10.1038\/s41565-018-0146-7.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"2641_CR239","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20(5):321\u201334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2641_CR240","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/acscentsci.9b01139","volume":"6","author":"W Yu","year":"2020","unstructured":"Yu W, Liu R, Zhou Y, Gao H. Size-tunable strategies for a tumor targeted drug delivery system. ACS Cent Sci. 2020;6(2):100\u201316. https:\/\/doi.org\/10.1021\/acscentsci.9b01139.","journal-title":"ACS Cent Sci"},{"issue":"18","key":"2641_CR241","doi-asserted-by":"publisher","first-page":"2009765","DOI":"10.1002\/adfm.202009765","volume":"31","author":"W Jia","year":"2021","unstructured":"Jia W, Wang Y, Liu R, Yu X, Gao H. Shape transformable strategies for drug delivery. Adv Func Mater. 2021;31(18):2009765. https:\/\/doi.org\/10.1002\/adfm.202009765.","journal-title":"Adv Func Mater"},{"issue":"9","key":"2641_CR242","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1039\/d0sc06557a","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Liu X, Pan W, Li N, Tang B. Intelligent stimuli-responsive nano immunomodulators for cancer immunotherapy. Chem Sci. 2021;12(9):3130\u201345. https:\/\/doi.org\/10.1039\/d0sc06557a.","journal-title":"Chem Sci"},{"issue":"10","key":"2641_CR243","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1021\/acs.accounts.0c00334","volume":"53","author":"L Li","year":"2020","unstructured":"Li L, Yang Z, Chen X. Recent advances in stimuli-responsive platforms for cancer immunotherapy. Acc Chem Res. 2020;53(10):2044\u201354. https:\/\/doi.org\/10.1021\/acs.accounts.0c00334.","journal-title":"Acc Chem Res"},{"key":"2641_CR244","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","volume":"126","author":"S Yang","year":"2017","unstructured":"Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res. 2017;126:97\u2013108. https:\/\/doi.org\/10.1016\/j.phrs.2017.05.004.","journal-title":"Pharmacol Res"},{"issue":"28","key":"2641_CR245","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1039\/d0sc00293c","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Gong S, Pan W, Chen Y, Liu B, Li N, et al. A tumor acidity activatable and Ca(2+)-assisted immuno-nanoagent enhances breast cancer therapy and suppresses cancer recurrence. Chem Sci. 2020;11(28):7429\u201337. https:\/\/doi.org\/10.1039\/d0sc00293c.","journal-title":"Chem Sci"},{"issue":"1","key":"2641_CR246","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41467-017-01050-0","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y, et al. Hollow MnO(2) as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017;8(1):902. https:\/\/doi.org\/10.1038\/s41467-017-01050-0.","journal-title":"Nat Commun"},{"issue":"2","key":"2641_CR247","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1021\/acs.molpharmaceut.7b00890","volume":"15","author":"X Liang","year":"2018","unstructured":"Liang X, Li X, Duan J, Chen Y, Wang X, Pang L, et al. Nanoparticles with CD44 targeting and ROS triggering properties as effective in vivo antigen delivery system. Mol Pharm. 2018;15(2):508\u201318. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00890.","journal-title":"Mol Pharm"},{"key":"2641_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124352","volume":"660","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Liu Y, Xie P, Yin Z. A ROS-responsive multifunctional targeted prodrug micelle for atherosclerosis treatment. Int J Pharm. 2024;660: 124352. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124352.","journal-title":"Int J Pharm"},{"issue":"10","key":"2641_CR249","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1021\/acs.nanolett.9b02306","volume":"19","author":"D Liu","year":"2019","unstructured":"Liu D, Chen B, Mo Y, Wang Z, Qi T, Zhang Q, et al. Redox-activated porphyrin-based liposome remote-loaded with indoleamine 2,3-dioxygenase (IDO) inhibitor for synergistic photoimmunotherapy through induction of immunogenic cell death and blockage of IDO pathway. Nano Lett. 2019;19(10):6964\u201376. https:\/\/doi.org\/10.1021\/acs.nanolett.9b02306.","journal-title":"Nano Lett"},{"issue":"4","key":"2641_CR250","doi-asserted-by":"publisher","first-page":"2002746","DOI":"10.1002\/advs.202002746","volume":"8","author":"F Sun","year":"2021","unstructured":"Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, et al. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer. Adv Sci. 2021;8(4):2002746. https:\/\/doi.org\/10.1002\/advs.202002746.","journal-title":"Adv Sci"},{"issue":"14","key":"2641_CR251","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/26\/14\/145102","volume":"26","author":"Y Liu","year":"2015","unstructured":"Liu Y, Ding X, Li J, Luo Z, Hu Y, Liu J, et al. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Nanotechnology. 2015;26(14): 145102. https:\/\/doi.org\/10.1088\/0957-4484\/26\/14\/145102.","journal-title":"Nanotechnology"},{"key":"2641_CR252","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/ncomms4364","volume":"5","author":"R Mo","year":"2014","unstructured":"Mo R, Jiang T, DiSanto R, Tai W, Gu Z. ATP-triggered anticancer drug delivery. Nat Commun. 2014;5:3364. https:\/\/doi.org\/10.1038\/ncomms4364.","journal-title":"Nat Commun"},{"key":"2641_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101083","volume":"37","author":"X Tang","year":"2021","unstructured":"Tang X, Sheng Q, Xu C, Li M, Rao J, Wang X, et al. pH\/ATP cascade-responsive nano-courier with efficient tumor targeting and siRNA unloading for photothermal-immunotherapy. Nano Today. 2021;37: 101083. https:\/\/doi.org\/10.1016\/j.nantod.2021.101083.","journal-title":"Nano Today"},{"key":"2641_CR254","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jconrel.2017.03.013","volume":"253","author":"VL Silva","year":"2017","unstructured":"Silva VL, Al-Jamal WT. Exploiting the cancer niche: tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy. J Controll Releas Off J Controll Releas Soc. 2017;253:82\u201396. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.013.","journal-title":"J Controll Releas Off J Controll Releas Soc"},{"issue":"11","key":"2641_CR255","doi-asserted-by":"publisher","first-page":"2008078","DOI":"10.1002\/adfm.202008078","volume":"31","author":"K Yang","year":"2021","unstructured":"Yang K, Yu G, Tian R, Zhou Z, Deng H, Li L, et al. Oxygen-evolving manganese ferrite nanovesicles for hypoxia-responsive drug delivery and enhanced cancer chemoimmunotherapy. Adv Func Mater. 2021;31(11):2008078. https:\/\/doi.org\/10.1002\/adfm.202008078.","journal-title":"Adv Func Mater"},{"issue":"5","key":"2641_CR256","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41585-019-0178-2","volume":"16","author":"KM Koo","year":"2019","unstructured":"Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nat Rev Urol. 2019;16(5):302\u201317. https:\/\/doi.org\/10.1038\/s41585-019-0178-2.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"2641_CR257","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.4497","volume":"24","author":"L Dardaei","year":"2018","unstructured":"Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512\u20137. https:\/\/doi.org\/10.1038\/nm.4497.","journal-title":"Nat Med"},{"key":"2641_CR258","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.csbj.2021.01.009","volume":"19","author":"O Menyh\u00e1rt","year":"2021","unstructured":"Menyh\u00e1rt O, Gy\u0151rffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021;19:949\u201360. https:\/\/doi.org\/10.1016\/j.csbj.2021.01.009.","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"2641_CR259","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","volume":"14","author":"A Goodman","year":"2017","unstructured":"Goodman A, Patel SP, Kurzrock R. PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203\u201320. https:\/\/doi.org\/10.1038\/nrclinonc.2016.168.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2641_CR260","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40824-023-00343-4","volume":"27","author":"M Kim","year":"2023","unstructured":"Kim M, Lee NK, Wang C-PJ, Lim J, Byun MJ, Kim T-H, et al. Reprogramming the tumor microenvironment with biotechnology. Biomater Res. 2023;27(1):5. https:\/\/doi.org\/10.1186\/s40824-023-00343-4.","journal-title":"Biomater Res"},{"key":"2641_CR261","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","volume":"8","author":"M Efremova","year":"2017","unstructured":"Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679. https:\/\/doi.org\/10.3389\/fimmu.2017.01679.","journal-title":"Front Immunol"},{"issue":"16","key":"2641_CR262","doi-asserted-by":"publisher","first-page":"2200027","DOI":"10.1002\/advs.202200027","volume":"9","author":"S Ruan","year":"2022","unstructured":"Ruan S, Huang Y, He M, Gao H. Advanced biomaterials for cell-specific modulation and restore of cancer immunotherapy. Adv Sci. 2022;9(16):2200027. https:\/\/doi.org\/10.1002\/advs.202200027.","journal-title":"Adv Sci"},{"issue":"1","key":"2641_CR263","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","volume":"41","author":"L Barthel","year":"2022","unstructured":"Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2022;41(1):53\u201375. https:\/\/doi.org\/10.1007\/s10555-021-09997-9.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"2641_CR264","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C. Liquid biopsy and minimal residual disease\u2014latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409\u201324. https:\/\/doi.org\/10.1038\/s41571-019-0187-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2641_CR265","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004029","author":"H Li","year":"2022","unstructured":"Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004029.","journal-title":"J Immunother Cancer."},{"issue":"25","key":"2641_CR266","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1038\/onc.2014.291","volume":"34","author":"W Du","year":"2015","unstructured":"Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene. 2015;34(25):3215\u201325. https:\/\/doi.org\/10.1038\/onc.2014.291.","journal-title":"Oncogene"},{"issue":"1","key":"2641_CR267","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery. 2024;10(1):40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9.","journal-title":"Cell Death Discovery"},{"issue":"8","key":"2641_CR268","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"2641_CR269","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1515\/ntrev-2021-0118","volume":"10","author":"W Mohamed","year":"2021","unstructured":"Mohamed W, Abd El-Gawad H, Mekkey S, Galal H, Handal H, Mousa H, et al. Quantum dots synthetization and future prospect applications. Nanotechnol Rev. 2021;10:1926\u201340. https:\/\/doi.org\/10.1515\/ntrev-2021-0118.","journal-title":"Nanotechnol Rev"},{"key":"2641_CR270","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036269","author":"ER Mardis","year":"2019","unstructured":"Mardis ER. The impact of next-generation sequencing on cancer genomics: from discovery to clinic. Cold Spring Harb Perspect Med. 2019. https:\/\/doi.org\/10.1101\/cshperspect.a036269.","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"1","key":"2641_CR271","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12967-024-05908-y","volume":"22","author":"ZF Yazdi","year":"2024","unstructured":"Yazdi ZF, Roshannezhad S, Sharif S, Abbaszadegan MR. Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis. J Transl Med. 2024;22(1):1173. https:\/\/doi.org\/10.1186\/s12967-024-05908-y.","journal-title":"J Transl Med"},{"issue":"1","key":"2641_CR272","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-022-01565-1","volume":"21","author":"SC Selvakumar","year":"2022","unstructured":"Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P, et al. CRISPR\/Cas9 and next generation sequencing in the personalized treatment of cancer. Mol Cancer. 2022;21(1):83. https:\/\/doi.org\/10.1186\/s12943-022-01565-1.","journal-title":"Mol Cancer"},{"issue":"4","key":"2641_CR273","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.Cd-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1808.","journal-title":"Cancer Discov"},{"issue":"3","key":"2641_CR274","doi-asserted-by":"publisher","first-page":"747","DOI":"10.31557\/APJCP.2024.25.3.747","volume":"25","author":"S Sarkar","year":"2024","unstructured":"Sarkar S, Srivastava TP, Sahoo OS, Shankar A, Rai A, Pethusamy K, et al. Applications of quantum dots in preventive oncology. Asian Pac J Cancer Prev. 2024;25(3):747\u201356. https:\/\/doi.org\/10.31557\/APJCP.2024.25.3.747.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2641_CR275","doi-asserted-by":"publisher","first-page":"e2103836","DOI":"10.1002\/advs.202103836","volume":"9","author":"S Peng","year":"2022","unstructured":"Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2022;9(1):e2103836. https:\/\/doi.org\/10.1002\/advs.202103836.","journal-title":"Adv Sci (Weinheim, Baden-Wurttemberg, Germany)"},{"issue":"5","key":"2641_CR276","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1039\/C9LC00550A","volume":"20","author":"L Wan","year":"2020","unstructured":"Wan L, Neumann CA, LeDuc PR. Tumor-on-a-chip for integrating a 3D tumor microenvironment: chemical and mechanical factors. Lab Chip. 2020;20(5):873\u201388. https:\/\/doi.org\/10.1039\/C9LC00550A.","journal-title":"Lab Chip"},{"key":"2641_CR277","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.660502","volume":"9","author":"J Pape","year":"2021","unstructured":"Pape J, Emberton M, Cheema U. 3D cancer models: the need for a complex stroma, compartmentalization and stiffness. Front Bioeng Biotechnol. 2021;9: 660502. https:\/\/doi.org\/10.3389\/fbioe.2021.660502.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"2641_CR278","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tibtech.2021.08.007","volume":"40","author":"MV Monteiro","year":"2022","unstructured":"Monteiro MV, Zhang YS, Gaspar VM, Mano JF. 3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models. Trends Biotechnol. 2022;40(4):432\u201347. https:\/\/doi.org\/10.1016\/j.tibtech.2021.08.007.","journal-title":"Trends Biotechnol"},{"issue":"1","key":"2641_CR279","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41598-021-81129-3","volume":"11","author":"I Boussaad","year":"2021","unstructured":"Boussaad I, Cruciani G, Bolognin S, Antony P, Dording CM, Kwon YJ, et al. Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening. Sci Rep. 2021;11(1):1439. https:\/\/doi.org\/10.1038\/s41598-021-81129-3.","journal-title":"Sci Rep"},{"issue":"9","key":"2641_CR280","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41592-021-01203-6","volume":"18","author":"SM Lewis","year":"2021","unstructured":"Lewis SM, Asselin-Labat ML, Nguyen Q, Berthelet J, Tan X, Wimmer VC, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods. 2021;18(9):997\u20131012. https:\/\/doi.org\/10.1038\/s41592-021-01203-6.","journal-title":"Nat Methods"},{"issue":"10","key":"2641_CR281","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24(10):695\u2013713. https:\/\/doi.org\/10.1038\/s41580-023-00615-w.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2641_CR282","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.tibtech.2022.02.004","volume":"40","author":"P Radfar","year":"2022","unstructured":"Radfar P, Aboulkheyr Es H, Salomon R, Kulasinghe A, Ramalingam N, Sarafraz-Yazdi E, et al. Single-cell analysis of circulating tumour cells: enabling technologies and clinical applications. Trends Biotechnol. 2022;40(9):1041\u201360. https:\/\/doi.org\/10.1016\/j.tibtech.2022.02.004.","journal-title":"Trends Biotechnol"},{"key":"2641_CR283","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1051\/vcm\/2021003","volume":"2","author":"L-L Guo","year":"2021","unstructured":"Guo L-L, Wang H-Y, Zheng L-S, Wang M-D, Cao Y, Li Y, et al. Metastasis of nasopharyngeal carcinoma: what we know and do not know. Visual Cancer Med. 2021;2:4.","journal-title":"Visual Cancer Med"},{"issue":"7871","key":"2641_CR284","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","volume":"596","author":"A Rao","year":"2021","unstructured":"Rao A, Barkley D, Fran\u00e7a GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596(7871):211\u201320. https:\/\/doi.org\/10.1038\/s41586-021-03634-9.","journal-title":"Nature"},{"key":"2641_CR285","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133170","author":"S van Dam","year":"2022","unstructured":"van Dam S, Baars MJD, Vercoulen Y. Multiplex tissue imaging: spatial revelations in the tumor microenvironment. Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14133170.","journal-title":"Cancers"},{"issue":"1","key":"2641_CR286","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41423-021-00727-3","volume":"19","author":"BI Reinfeld","year":"2022","unstructured":"Reinfeld BI, Rathmell WK, Kim TK, Rathmell JC. The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cell Mol Immunol. 2022;19(1):46\u201358. https:\/\/doi.org\/10.1038\/s41423-021-00727-3.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"2641_CR287","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","volume":"20","author":"J Bi","year":"2020","unstructured":"Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas\u2014an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20(1):57\u201370. https:\/\/doi.org\/10.1038\/s41568-019-0226-5.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2641_CR288","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/10408363.2019.1660303","volume":"56","author":"DJ Schwartz","year":"2019","unstructured":"Schwartz DJ, Rebeck ON, Dantas G. Complex interactions between the microbiome and cancer immune therapy. Crit Rev Clin Lab Sci. 2019;56(8):567\u201385. https:\/\/doi.org\/10.1080\/10408363.2019.1660303.","journal-title":"Crit Rev Clin Lab Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02641-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02641-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02641-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:37:04Z","timestamp":1743367024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02641-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":288,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2641"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02641-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"117"}}